Therapy for Progressing Lung Cancer Not'One Size Fits All'Therapy for Progressing Lung Cancer Not'One Size Fits All '

Treating lung cancer progression may require biopsies, targeted therapies, or chemotherapy, but it should always include listening closely to the patient, says Dr Mark Kris.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Related Links:

This study aimed to estimate therapeutic effects of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in real-world practice, by analyzing survival outcomes in an unselected, Korean female population with advanced lung cancer based on the National Health Insurance Service database. METHODS:: We identified women with newly diagnosed advanced lung cancer from January 2004 to December 2013. For progression-free survival (PFS) and overall survival (OS) analyses, patients were defined into the following subgroups: group A, treated with first-generation EGFR-TKI ⩾6 months; group B, tr...
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
Authors: Muñoz-Largacha JA, Rao SR, Brinckerhoff LH, Daly BD, Fernando HC, Litle VR, Suzuki K Abstract OBJECTIVE:: To determine if induction chemotherapy with concurrent high-dose radiation followed by resection is associated with improved survival in patients with nonsuperior sulcus lung cancer with chest wall invasion. METHODS:: We performed a retrospective review of clinical T3 (chest wall invasion) N0/N1 patients with non-small cell lung cancer who underwent surgical resection between January 1, 1992, and January 31, 2017. Exclusion criteria included superior sulcus tumors and resection performed for...
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
Thoracic surgeon Dr. Robert Cameron and the Pacific Mesothelioma Center moved closer to a major treatment advance by obtaining U.S. patent approval for their novel mesenchymal stem cell research program. The patent approval in February makes the research program more attractive to potential investors who could accelerate development and change the way malignant mesothelioma is treated. “This is a big deal in the developmental path for MSC [mesenchymal stem cell] therapy,” Patent Adviser Dr. Walid Sabbagh told The Mesothelioma Center at “The patent is a pathway to really help these cancer pat...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Lung cancer is a leading cause of cancer-related deaths worldwide [1]. Approximately 85% of patients with lung cancer are diagnosed with non-small cell lung cancer (NSCLC). Because two-thirds of the patients show local advancement or have metastatic tumors at diagnosis, chemotherapy is the major strategy for the treatment of lung cancer. Molecular targeted therapies for the treatment of lung cancer have developed remarkably in the past two decades and therapies that target driver mutations, such as EGFR mutations and ALK protein fusions, are the major treatment strategies for patients with NSCLC.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Authors: Bewersdorf JP, Stahl M, Zeidan AM Abstract INTRODUCTION: Immune system evasion is essential for tumor cell survival and is mediated by the immunosuppressive tumor microenvironment and the activation of inhibitory immune checkpoints. While immune checkpoint-based therapy yielded impressive results in several advanced solid malignancies such as melanoma and non-small cell lung cancer, its role in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) is still evolving. Areas covered: Here we review the immunology in the tumor microenvironment in the bone marrow and discuss the current preclinical an...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Enhanced Recovery after Surgery (ERAS) integrates multiple evidence-based interventions to accelerate postoperative recovery. We hypothesized that ERAS would also facilitate adjuvant chemotherapy for non-small cell lung cancer (NSCLC).
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Source Type: research
Lung cancer is a leading cause of death due to cancer in many countries, including Japan [1]. Non-small-cell lung cancer (NSCLC) accounts for 85 –90% of lung cancers [2]. Approximately 70% of NSCLC patients are diagnosed with advanced or metastatic disease that is not amenable to surgical resection, and the prognosis remains poor [3]. However, in the previous two decades several new antineoplastic agents have been approved for the treatmen t of NSCLC in Japan (Figure 1). In the 1990s, several cytotoxic agents (CAs) were approved, and the role of chemotherapy in the treatment of stage IV NSCLC was established by 1995 [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsMTV and glu-SUVmax measured on pretreatment18F-FDG PET/CT were independent prognostic factors for LD-SCLC patients after chemoradiotherapy with curative intent. These metabolic markers need validation in larger prospective studies but may be useful in the clinical care of LD-SCLC patients.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: The atypical presentation of gallbladder metastases could mislead treating providers. The diagnosis might alter management decisions and prognosis.Case Rep Oncol 2019;12:235 –240
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Hematology | Lung Cancer